Email this article Chronic gastrite: modern state of the problem
- Authors: Minushkin O.N.1, Zverkov I.V.1, Lvova N.V.2, Skibina Y.S.1, Inevatova V.S.3
-
Affiliations:
- Central State Medical Academy of Department of Presidential Affairs
- Moscow Research and Practical Centre for of Medical Rehabilitation, Restorative and Sports Medicine
- ICC Chekhov Branch
- Issue: Vol 92, No 8 (2020)
- Pages: 18-23
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/43536
- DOI: https://doi.org/10.26442/00403660.2020.08.000693
- ID: 43536
Cite item
Full Text
Abstract
Aim. Тo evaluate the modern view on the problem of chronic gastritis and the effectiveness of the drug ursodexic acid (UHC) Grinterol in the treatment of patients with chronic antral reflux-gastritis (biliar).
Materials and methods. The work provides modern ideas about chronic gastritis, the issues of etiology and pathogenesis are considered. Contemporary classifications and the attitude of the authors of the work to them are presented. Clinical studies were conducted in 50 patients with chronic antral reflux-gastritis biliary (32 women and 18 men) between the ages of 20 and 80 years (average age – 50.3 to 8.0 years). The treatment uses the drug Grinterol in a daily dose of 12.5 mg/kg of body weight for 4 weeks.
Results. Among patients with chronic antral gastritis isolated patients with reflux-gastritis biliary, the pathogenetic factor of which is the damaging property of aggressive bile acids. The main treatment for such patients are drugs UHC (in this study (this study uses Grinterol at a daily dose of 12.5 mg/kg of body weight); the duration of treatment is 4 years. The overall efficiency (according to endomorphological data) was 76%, according to clinical data – 100%.
Discussion. Critical consideration of the classifications used and proposed for consideration indicates that the time has come for the adoption of a new classification with the allocation of reflux-gastritis biliary. Treatment of this form of antral gastritis is effective with UDHC drugs.
Conclusion. the selection of a form of antral reflux-gastritis biliar in a separate classification group is scientifically justified. The results suggest that for the treatment of patients with chronic biliary refluxdrugs of choice are drugs UDHC.
Full Text
##article.viewOnOriginalSite##About the authors
O. N. Minushkin
Central State Medical Academy of Department of Presidential Affairs
Author for correspondence.
Email: oleg.minushkin@bk.ru
ORCID iD: 0000-0002-7723-7992
д.м.н., проф., зав. каф. гастроэнтерологии ЦГМА
Russian Federation, MoscowI. V. Zverkov
Central State Medical Academy of Department of Presidential Affairs
Email: oleg.minushkin@bk.ru
ORCID iD: 0000-0001-6210-8955
д.м.н., проф. каф. гастроэнтерологии ЦГМА
Russian Federation, MoscowN. V. Lvova
Moscow Research and Practical Centre for of Medical Rehabilitation, Restorative and Sports Medicine
Email: oleg.minushkin@bk.ru
ORCID iD: 0000-0002-0840-4590
к.м.н., вед. науч. сотр. МНПЦМРВСМ
Russian Federation, MoscowYu. S. Skibina
Central State Medical Academy of Department of Presidential Affairs
Email: oleg.minushkin@bk.ru
ORCID iD: 0000-0002-3946-4983
к.м.н., врач-лаборант каф. гастроэнтерологии
Russian Federation, MoscowV. S. Inevatova
ICC Chekhov Branch
Email: oleg.minushkin@bk.ru
ORCID iD: 0000-0002-9678-342X
зав. отд. гастроэнтерологии АО «МЦК Чеховский филиал»
Russian Federation, ChekhovReferences
- Минушкин О.Н. Хронический гастрит: представления, диагностика, лечебные подходы. Мед. совет. 2007;1:71-6 [Minushkin ON. Chronic gastritis: representations, diagnosis, therapeutic approaches. Medical advice. 2007;1:71-6 (In Russ.)].
- Бурдина Е.Г., Минушкин О.Н., Зверков И.В. Рациональная формакотерапия хронического гастрита. Эффективная фармакотерапия. 2009;1:1-5 [Burdina EG, Minushkin ON, Zverkov IV. Rational formotherapy of chronic gastritis. Effective pharmacotherapy. 2009;1:1-5 (In Russ.)].
- Гастроэнтерология. Национальное руководство. Под ред. В.Т. Ивашкина, Т.Л. Лапиной. М., 2008 [Gastroenterology. National guideline. Ed. by VT Ivashkin, TL Lapina. Moscow, 2008 (In Russ.)].
- Яковенко Э.П. Хронический гастрит, диагностика и лечение. Фарматека. 2009;8:50-4 [Yakovenko EP. Chronic gastritis, diagnosis and treatment. Farmateka. 2009;8:50-4 (In Russ.)].
- Bechi P, Cianchi F, Mazzanti R, et al. Reflux and pH: ‘alkaline’ components are not neutralized by gastric pH variations. Dis Esophag. 2000;13(1):51-5. doi: 10.1046/j.1442-2050.2000.00063.x. PMID: 11005332.
- Tanaka A, Tokunaga K, Takahashi S. The practical assessment of H. pylori eradication. Nihon Risho. 2013;71(8):1388-93.
- Sugano K, Tack J, Kuipers EJ, et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
- Маев И.В., Андреев Д.Н., Самсонов А.А. и др. Эволюция представлений о дефиниции, классификации, диагностике и лечении гастрита, ассоциированного с инфекцией Helicobacter pylori. Фарматека. 2016;6:24-33 [Maev IV, Andreev DN, Samsonov AA, et al. The evolution of ideas about the definition, classification, diagnosis and treatment of gastritis associated with Helicobacter pylori infection. Farmateka. 2016;6:24-33 (In Russ.)].
- Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 Apr;51(4):365-88. doi: 10.1055/a-0859-1883. PMID: 30841008.
- Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013;2:66-72 [Maev IV, Samsonov AA, Andreev DN. The role and place of antacids in modern algorithms for the treatment of acid-dependent diseases. Farmateka. 2013;2:66-72 (In Russ.)].
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
- Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;89(8):5-12. doi: 10.17116/terarkh20178985-12 [Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Therapeutic Archive. 2017;89(8):5-12 (In Russ.)]. doi: 10.17116/terarkh20178985-12
- Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
- Лоранская И.Д., Ракитская Л.Г., Мамедова Л.Д. Применение препарата «Пепсан Р» в лечении гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая гастроэнтерология. 2008;4:1-4 [Loranskaya ID, Rakitskaya LG, Mamedova LD. The use of the drug «Pepsan R» in the treatment of gastroesophageal reflux disease. Experimental and clinical gastroenterology. 2008;4:1-4 (In Russ.)].
- Минушкин О.Н. Антацидные средства в лечении гастроэзофагеальной рефлюксной болезни. Фарматека. 2007;6:1-3 [Minushkin ON. Antacids in the treatment of gastroesophageal reflux disease. Farmateka. 2007;6:1-3 (In Russ.)].
- Препараты урсодезоксихолевой кислоты в клинической практике. Методическое пособие. Изд. 2-е. 2016 [Ursodeoxycholic acid preparations in clinical practice. Toolkit. Ed. 2nd. 2016 (In Russ.)].
